<DOC>
	<DOCNO>NCT01181427</DOCNO>
	<brief_summary>Study ABT-267 healthy volunteer Hepatitis C virus ( HCV ) genotype 1 infected subject .</brief_summary>
	<brief_title>Study ABT-267 Both Healthy Volunteers Hepatitis C Virus ( HCV ) Genotype 1 Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Cytochrome P-450 Enzyme Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Main Selection Criteria Healthy Volunteers : Subject provide write consent . Subject general good health . Females must postmenopausal least 2 year surgically sterile . Females must pregnant breastfeeding . If male , subject surgically sterile practice specific form birth control . Main Selection Criteria HCV Genotype 1infected Volunteers : Subject provide write consent . Subject chronic HCV genotype 1 infection screening . Liver biopsy within 3 year histology . Females must postmenopausal least 2 year surgically sterile . Females must pregnant breastfeeding . If male , subject surgically sterile practice specific form birth control . Subject general good health , perceive investigator , HCV infection . Main Selection Criteria Volunteers Resistance Monitoring Portion Study : Subject provide write consent , receive least one dose ABT267 placebo study , consider suitable investigator participate . Exclusion Criteria Main Exclusion Criteria Healthy Volunteers : Positive test HAV IgM , HBsAg , HCV Ab HIV Ab . Clinically significant cardiovascular , respiratory ( except mild asthma ) , renal , gastrointestinal , hematologic , neurologic , thyroid , uncontrolled medical illness psychiatric disorder . Use tobacco nicotinecontaining product 6month period prior study drug administration . Abnormal screen laboratory result . Significant sensitivity drug . Requirement counter and/or prescription medication , vitamins and/or herbal supplement regular basis . Main Exclusion Criteria HCV Genotype 1infected Volunteers : Significant sensitivity drug . Positive HBsAg , HAVIgM , HIV Ab . Use CYP enzyme inducer inhibitor within 1 month dosing . Clinically significant cardiovascular , respiratory ( except mild asthma ) , renal , gastrointestinal , hematologic , neurologic , thyroid disease ( except hypothyroidism stable thyroid replacement therapy ) , uncontrolled medical illness psychiatric disorder . Use medication ( prescription overthe counter ) within 2 week prior study drug dosing without prior approval Abbott Medical Monitor . Use vitamins herbal supplement within 2 week prior study drug dosing . Prior treatment investigational commercially available antiHCV agent . Abnormal screen laboratory result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>